Pedro Sánchez-Rovira, MD, PhD

home / authors / pedro-sánchez-rovira-md-phd

Articles

Site Logo

Biweekly Gemcitabine, Doxorubicin, and Paclitaxel as First-Line Treatment in Metastatic Breast Cancer

Pedro Sánchez-Rovira, MD, PhD;Ana Jaén, MD;Encarna González, MD;Ignacio Porras, MD;Rosario Dueñas, MD;Begoña Medina, MD;Nicolás Mohedano, MD;Margarita Fernández, MD;Maximiliano Martos, MD;Ana Lozano, MD;Eva Carrasco, MD
February 1st 2001

In a single-center, open, phase II trial, we assessed the toxicity and activity of a triple combination therapy-doxorubicin at 30 mg/m2 (day 1), paclitaxel (Taxol) at 135 mg/m2 (day 2), and gemcitabine (Gemzar) at 2,500 mg/m2

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma
Published: May 11th 2022 | Updated: April 5th 2025
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma